my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
24-06-2011: Abbott and Biotest AG announced a global agreement to develop and commercialize BT-061, a novel anti-CD4 antibody for the treatment of rheumatoid arthritis (RA) and psoriasis. BT-061 is currently in Phase II clinical trials for RA and psoriasis, with preclinical studies underway to study its potential use in other immune-related diseases.
CD4 is expressed on T-cells and is involved in T-cell mediated modulation of immune responses. BT-061 is a humanized monoclonal antibody that works by activating the body's T-regulatory cells, a subset of T-cells, strengthening a natural function of the body that prevents excessive immune reactions. Unlike other anti-CD4 antibodies that have been in development, BT-061 does not cause depletion of CD4 positive T-cells that would give rise to weakened immune responses.
Under the terms of the agreement, Abbott and Biotest will co-promote BT-061 in the five major European markets (Germany, France, United Kingdom, Italy and Spain) and Abbott will have exclusive global rights to commercialize BT-061 outside those countries. Biotest will receive an upfront fee of $85MM. Pending achievement of certain development, regulatory, commercial and sales-based milestones, Biotest would be eligible to receive additional milestone payments from Abbott, potentially amounting to a total of $395MM, and royalties. Biotest will be responsible for manufacturing the initial clinical supply of BT-061 and the companies will share responsibility for commercial production.
Contact / Request information
Request further information free of charge:
Watchlist
This is where you can add this news to your personal favourites
Abbott completes separation of research-based pharmaceuticals business
Abbott announced it has completed the separation of its research-based pharmaceuticals business, which became AbbVie, a new independent biopharmaceutical company. AbbVie begins trading independently on the New York Stock Exchange under the symbol "ABBV." "We wish our colleagues at AbbVie c ... more
Abbott's HUMIRA (Adalimumab) Approved in Europe for Severe Active Pediatric Crohn's Disease
Abbott announced that the European Commission has approved HUMIRA® (adalimumab) for the treatment of pediatric patients aged 6 to 17 years with severe active Crohn's disease (CD) who failed, are intolerant to, or have contraindications to conventional therapy. With this approval, HUMIRA bec ... more
Abbott to Collaborate with Astellas in CMV Vaccine Trial
Abbott announced that it has signed an agreement to collaborate with Astellas Pharma Global Development in a Phase 3 clinical trial for ASP0113 (TransVax™), an investigational vaccine licensed from Vical Incorporated for preventing cytomegalovirus (CMV) reactivation in transplant patients.U ... more
Abbott de Mexico, S.A. de C.V.
We are a global, broad-based health care company devoted to discovering new medicines, new technologies and new ways to manage health. Our products span the continuum of care, from nutritional products and laboratory diagnostics through medical devices and pharmaceutical therapies. Our comp ... more
To meet the ever growing needs of modern medicine and combat emerging new diseases, there is a constant demand for improved diagnostic methods, therapeutic approaches and technologies. As a leading manufacturer of health care products, it is Abbott's goal to meet these needs worldwide. In G ... more
To meet the ever growing needs of modern medicine and combat emerging new diseases, there is a constant demand for improved diagnostic methods, therapeutic approaches and technologies. As a leading manufacturer of health care products, it is Abbott's goal to meet these needs worldwide. In G ... more
Biotest AG: First time Revenue and EBIT contribution by Biotherapeutics Segment
The Biotest Group has increased sales in the first half of 2011 in it's continuing operations (Plasma Proteins and Biotherapeutics) by 4,9 % to EUR 212,9 million compared to EUR 202.9 million in the previous year period. The increase was largely attributable to an upfront payment under a de ... more
Merck Millipore Completed Acquisition of Microbiology Business of Biotest AG
Merck Millipore announced that it has completed the acquisition of the microbiology business of Biotest AG, Dreieich, Germany. All relevant authorities approved the sale of Biotest´s woldwide Microbiological Monitoring business activities, which consist of the product portfolio of Hycon (hy ... more
Abbott and Biotest AG announced a global agreement to develop and commercialize BT-061, a novel anti-CD4 antibody for the treatment of rheumatoid arthritis (RA) and psoriasis. BT-061 is currently in Phase II clinical trials for RA and psoriasis, with preclinical studies underway to study it ... more
Biotest is a company specialising in innovative haematology and immunology products with the holistic approach of a global pharmaceutical, diagnostics and biotherapeutics group. Its approximately 2,000 employees develop, manufacture and sell medicinal products for the treatment of blood and ... more
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
